Cibus Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Cibus Inc (CBUS) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Cibus Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 4M vs 17,862M combined for its competitors (0.0% combined share).
- Trending: Latest-quarter revenue run-rate is decelerating (-8.5% annualized vs trailing 12 months), vs accelerating (+42.9%) for its tracked peer group.
- Growth: Cibus Inc generated 6.5% revenue growth year over year in Q2 2026, vs -1.2% for its competitors combined.
- Profitability: Its -2,227.9% net margin compares with 17.7% for the peer group.
- Scale: Cibus Inc ranks #22 of 44 companies by market capitalization in the Agricultural Production industry, holding 0.1% of industry market cap.
- Peer revenue share: Cibus Inc accounted for 0.0% of combined revenue among its tracked peer group, up from 0.0% a year earlier.
- Peer differentiation: Revenue per employee of $0.04M compares with $0.83M for the peer group (0.0x).
- Structure: Cibus Inc operates in the following segments: Reportable.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
CBUS Sales vs. its Competitors, Q2 2026
Cibus Inc reported revenue growth of 6.54 % year on year in Q2 2026, above its competitors' combined revenue change of -1.19 %.
With a net margin of -2,227.87 %, Cibus Inc reported lower profitability than its competitors (17.65 %).
Cibus Inc generated 0.02 % of the combined sales of its peer group, up from 0.01 % a year earlier.
API endpoints for this dataset
Cibus Inc vs. its Competitors, Q2 2026
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in Cibus Inc reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Cibus Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Cibus Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| Similar-Size Competitors (8) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Cibus Inc's competitor groups requires a Commercial License.
For context: the Agricultural Production industry grew revenue 7.5% year over year, combined, vs 6.5% for Cibus Inc. Cibus Inc's share of combined industry revenue moved from 0.00% to 0.00%, a gain of 0.00 percentage points.
Cibus Inc's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Cibus Inc | - | No | No | No |
| Competitors combined (3) | ||||
| Similar-Size Competitors (10) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
CBUS Stock Performance relative to its Competitors
CBUS Stock Performance relative to Similar-Size Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Precision Biosciences Inc | 282.9% | Outperformed |
| 2 | Corteva Inc | 282.9% | Outperformed |
| 3 | Arcadia Biosciences Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Cibus Inc's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Cibus Inc's Comment on Competition and Industry Peers
Publicly Traded Peers of Cibus Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Cibus Inc |
92.11 | 4.35 |
 Corteva Inc |
8,071.09 | 17,812.00 |
 Precision Biosciences Inc |
273.29 | 45.07 |
 Arcadia Biosciences Inc |
0.46 | 4.75 |
| SUBTOTAL | 8,436.95 | 17,866.17 |
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Cibus Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Cibus Inc's Competitors Named by the Company
Competitive relationships identified from Cibus Inc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Precision Biosciences Inc | Company report | 85% |
| Corteva Inc | Company report | 85% |
| Arcadia Biosciences Inc | Company report | 85% |
| Benson Hill Inc | Company report | 85% |
Company report basis, confidence, active dates and source counts for Cibus Inc's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Cibus Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Cibus Inc | Reportable 100.00 % |
| Corteva Inc | Seed 71.05 % |
| Precision Biosciences Inc | Operating 100.00 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Cibus Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Cibus Inc | 92 | 36,839 | -844,220 |
| Corteva Inc | 8,071 | 828,465 | 47,488 |
| Precision Biosciences Inc | 273 | 662,838 | -566,853 |
| Arcadia Biosciences Inc | 0 | 593,250 | -1,391,375 |
| PEERS TOTAL | 8,345 | 827,856 | 45,019 |
Cibus Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 38 companies in Cibus Inc's industry classification, broader than the peer set above. Market cap in millions of $.Cibus Inc ranks #22 of 38 companies by market capitalization in its industry, holding 0.06 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 1,545, indicating a moderately concentrated market structure (see Methodology: Market Structure & Concentration).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Nutrien Ltd | 34,776 | 23.94 % |
| 2 | Archer daniels midland Co | 33,935 | 23.36 % |
| 3 | Bunge Global Sa | 19,358 | 13.32 % |
| 4 | Cf Industries Holdings inc | 18,374 | 12.65 % |
| 5 | Darling Ingredients Inc | 1,234 | 5.2% |
| 6 | Mosaic Co | 1,234 | 5.2% |
| 7 | Icl Group Ltd | 1,234 | 5.2% |
| 8 | Scotts Miracle gro Co | 1,234 | 5.2% |
| 9 | Seaboard Corporation | 1,234 | 5.2% |
| 10 | Andersons Inc | 1,234 | 5.2% |
| 22 | Cibus Inc | 91 | 0.06 % |
Market cap and industry share for the rest of Cibus Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-11-06.
Cibus Inc's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 17 | Village Farms International Inc | 362 | -10.61 % |
| 18 | Brasilagro Brazilian Agricultural Real Estate Company | 324 | -15.04 % |
| 19 | Alico Inc | 276 | 14.69 % |
| 20 | Cea Industries Inc | 258 | -14.66 % |
| 21 | Limoneira Company | 1,234 | 12.3% |
| 22 | Cibus Inc | 91 | -11.41 % |
| 23 | Golden Growers Cooperative | 1,234 | 12.3% |
| 24 | Rythm Inc | 1,234 | 12.3% |
| 25 | American Vanguard Corporation | 1,234 | 12.3% |
| 26 | Local Bounti Corporation | 1,234 | 12.3% |
| 27 | Bioceres Crop Solutions Corp | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Cibus Inc's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-11-06. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Cibus Inc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Agricultural Production industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (68 companies). See the full Agricultural Production industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 0.00 % | 15.30 % (avg) | -15.3 pp |
| Operating Margin | - | industry median | - |
| EBITDA Margin | - | 1.88 % (avg) | - |
| Capital Intensity (Capex / Revenue) | 6.14 % | 4.90 % (avg) | +1.2 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Cibus Inc's Valuation vs Competitive Position
Valuation multiples vs the Agricultural Production industry average (68 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Agricultural Production industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 18.7x | - |
| EV / EBITDA | - | 9.9x | - |
| P/B | 3.5x | 1.9x | +1.6x |
| Return on Equity | -320.99 % | industry aggregate | -328.28 % |
| Return on Invested Capital | -18.92 % | -2.59 % (avg) | -16.33 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Cibus Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue Growth | 500.00 % | 226.91 % | 8.96 % | -99.40 % | 500.00 % | 134.56 % | -14.62 % |
| Operating Margin | -543.76 % | -183.77 % | -112.87 % | -14,248.41 % | - | - | - |
| Return on Invested Capital | -23.38 % | -42.45 % | -50.81 % | -62.00 % | -40.34 % | -42.00 % | -26.62 % |
| P/E | - | - | - | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Cibus Inc's BCG Growth-Share Matrix
See Methodology: BCG Growth-Share Matrix for how relative share and growth are calculated and thresholded.
Cibus Inc falls in the Dog quadrant: relative market share of 0.00x vs its largest competitor, in an industry growing revenue 4.6% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution.
Cibus Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | Moderate | Industry HHI of 1,545 (see Industry Market Structure & Concentration above) |
| Barriers to Entry | High (capital intensive) | Capital intensity (capex / revenue) of 6.14 % vs industry average 4.90 % (see Profitability & Cost Structure above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Cibus Inc's dedicated Suppliers and Customers pages, not here.
Cibus Inc's Industry Attractiveness & Competitive Strength
See Methodology: GE/McKinsey Matrix for how the two axes are built.
Cibus Inc falls in the Low attractiveness / Low strength cell: Harvest / Divest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Cibus Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
No rule matched.
Weaknesses
- Return on equity 328.3 points below the industry aggregate.
- Latest-quarter revenue run-rate is decelerating (-8.5% annualized vs trailing 12 months).
- Underperforming the U.S.A. 500 over the trailing 12 months.
- Low relative market share vs the industry leader (0.00x).
Opportunities
- A meaningful share of competitors (33.30 %) show financial-distress signals, a possible opening to gain share.
Threats
- High capital intensity requires continuous reinvestment just to keep pace with the industry.
Methodology: see Methodology: SWOT Analysis.
Cibus Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Cibus Inc | 1.28 | 1.44 | 0.02 |
| Corteva Inc | 0.25 | 1.49 | 0.15 |
| Precision Biosciences Inc | 11.78 | 12.64 | 0.34 |
| Arcadia Biosciences Inc | 0.89 | 3.49 | - |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Cibus Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Cibus Inc | Q2 2026 | +6.5 % | - |
| Corteva Inc | Q2 2026 | -1.2 % | -11.5 % |
| Precision Biosciences Inc | Q3 2026 | - | - |
| Arcadia Biosciences Inc | Q2 2026 | -0.8 % | - |
| PEERS TOTAL | -1.2 % | -10.6 % |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Cibus Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Cibus Inc | Q2 2026 | - | - |
| Corteva Inc | Q2 2026 | -7.3 % | +3.4 % |
| Precision Biosciences Inc | Q3 2026 | - | - |
| Arcadia Biosciences Inc | Q2 2026 | -1.5 % | - |
Cibus Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Cibus Inc | - | - | - |
| Corteva Inc | 2.41% | 3.42% | 4.09% |
| Precision Biosciences Inc | - | - | - |
| Arcadia Biosciences Inc | - | - | - |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Cibus Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Cibus Inc | - | 21.19 |
| Corteva Inc | 7.93 | 0.45 |
| Precision Biosciences Inc | - | 6.06 |
| Arcadia Biosciences Inc | - | 0.10 |
| PEERS AVERAGE | 9.68 | 0.47 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.